The Problem We’re Solving
75% of all cancer drugs fail due to patients' unique genetic profiles.
Patients endure unnecessary side effects with little to no benefit.
Current treatment decisions are made without sufficient personalized insight.
Delivering Personalized Medicines with Integrity and Innovation
At EthicaMeds, we’re redefining the future of medicine — not by putting profits first, but by ensuring that every patient receives the medicine most likely to work for them.
75% of all cancer drugs fail due to patients' unique genetic profiles.
Patients endure unnecessary side effects with little to no benefit.
Current treatment decisions are made without sufficient personalized insight.
We're turning the pharmaceutical and diagnostic world on its head.
Using patent-pending, Nobel-caliber technology and datasets, we've developed a way to:
GigaAssay™: High-throughput testing of millions of genetic variants for drug response.
Genomic Multiplex Library (GML): Enables large-scale, real-time genetic analysis.
Outcome: The right medicine for the right patient, backed by real-world functional data.
Screened 20,000 biologic variants for real-world efficacy.
Selected biosimilars based on functional performance, not theory.
Personalized delivery ensures patients receive the best-matched medicine.
Faster, more affordable approvals: < $10M and 2-3 years versus traditional $50M and 5-10 years.
$200B+ Global Oncology Drug Market
HER2+ Breast Cancer — a multi-billion dollar focus market.
Personalized Medicine Market projected to reach $175B+ by 2030.
Launch with HER2+ precision medicine.
Expand to ERBB2-related cancers and broader oncology.
Enter 13 international markets with streamlined regulatory pathways.
Advance towards FDA and EU approvals for broader reach.
Include precision genetic testing at minimal cost with each medicine.
Generate revenue through direct personalized medicine delivery.
Partner with healthcare providers and clinics.
Set a new global standard for ethical medicine distribution.
